BMY•benzinga•
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
Summary
Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 15, 2025 by benzinga